FDA approves prostate cancer “vaccine”BMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c2431 (Published 04 May 2010) Cite this as: BMJ 2010;340:c2431
- Janice Hopkins Tanne
- 1New York
The US Food and Drug Administration last week approved the first therapeutic “vaccine” against cancer.
Provenge (sipuleucel-T), made by Dendreon, a company in Seattle, Washington, does not prevent cancer. The individualised treatment is designed to induce a patient’s own cells to attack metastatic prostate cancer that is causing few or no symptoms but that no longer responds to hormone therapy.
Trial results show that Provenge extended men’s lives by an average of 4.1 months, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial